2. Search Result
Search Result
Results for "

Ravtansine

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

8

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12454
    DM4
    4 Publications Verification

    Ravtansine

    		 Microtubule/Tubulin ADC Payload Cancer
    DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.
    DM4
  • HY-141606
    Anetumab ravtansine

    BAY 94-9343

    		 Microtubule/Tubulin Antibody-Drug Conjugates (ADCs) Cancer
    Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
    Anetumab ravtansine
  • HY-141607
    Indatuximab ravtansine

    BT-062; nBT062-DM4

    		 Antibody-Drug Conjugates (ADCs) Bacterial Cancer
    Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .
    Indatuximab ravtansine
  • HY-P99493
    Cantuzumab ravtansine

    IMGN242; huC242-DM4

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
    Cantuzumab ravtansine
  • HY-P99542
    Tusamitamab ravtansine

    SAR-408701; HuMAb2-3-SPDB-DM4

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
    Tusamitamab ravtansine
  • HY-P99788
    Praluzatamab

    		ADC Antibody ALCAM/CD166 Cancer
    Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
    Praluzatamab
  • HY-P99054
    Tusamitamab

    		Transmembrane Glycoprotein ADC Antibody Cancer
    Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .
    Tusamitamab
  • HY-P99967
    Cantuzumab

    		ADC Antibody Cancer
    Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
    Cantuzumab
  • HY-P99352
    Anetumab

    Anti-MSLN Antibody

    		 Mesothelin ADC Antibody Cancer
    Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer .
    Anetumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: